Combining TGF-β blockade with immune checkpoint blockade in mouse models increases the anti-tumour efficacy of the therapy, suggesting that identifying and targeting microenvironmental regulators of anti-tumour immunity may increase the reach of immunotherapeutical approaches [32]. The gene discussed is TGFB1; the disease is neoplasm.